Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 14, 2013, Pages 1999-2013

  Zhang, Li ^b   Lei, Jine ^a   Shan, Yuanyuan ^a   Yang, Hao ^c   Song, Maxiaowei ^a   Ma, Ying ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^c Shaanxi Provincial Tumor Hospital   (China)

Author keywords

Anticancer agent; HDAC inhibitor; Histone deacetylase (HDAC); Structure activity relationship (SAR)

Indexed keywords

2 AMINO BENZANILIDE DERIVATIVES; 2 AMINOANILIDE DERIVATIVES; ABEXINOSTAT; APICIDIN; AZUMAMIDE A; AZUMAMIDE E; BELINOSTAT; DIPHENYLMETHYLENE HYDROXAMIC ACID; ELECTROPHILIC KETONE DERIVATIVES; ENTINOSTAT; FR 235222; GIVINOSTAT; HC TOXIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVES; KD 5150; MACROCYCLIC DERIVATIVES; MOCETINOSTAT; PANOBINOSTAT; QUISINOSTAT; RESMINOSTAT; ROMIDEPSIN; SELENIUM DERIVATIVES; SPIRUCHOSTATIN C; SULFAMIDE DERIVATIVES; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; EPIGENETICS; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LEUKEMIA; MYELOMA; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; UTERINE CERVIX CANCER;

ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL PRODUCTS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; KETONES; MACROCYCLIC COMPOUNDS; NEOPLASMS;

EID: 84892957575     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113136660102     Document Type: Review

References (108)

1. Chou, Y. W.; Chaturvedi, N. K.; Ouyang, S.; Lin, F. F.; Kaushik, D.; Wang, J.; Kim, I.; Lin, M. F. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Lett., 2011, 311(2), 177-186.
2. Leggatt, G. R.; Gabrielli, B. Histone deacetylase inhibitors in the generation of the anti-tumour immune response. Immunol Cell Biol., 2012, 90(1), 33-38.
3. Ropero, S.; Esteller, M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol., 2007, 1(1), 19-25.
4. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet., 2009, 10(1), 32-42.
5. Neal, J. W.; Sequist, L. V. Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. J. Clin. Oncol., 2012, 30(18), 2280-2282.
6. Wanczyk, M.; Roszczenko, K.; Marcinkiewicz, K.; Bojarczuk, K.; Kowara, M.; Winiarska, M. HDACi--going through the mechanisms. Front Biosci (Landmark Ed)., 2011, 1, 16: 340-359.
7. Xu, W. S.; Parmigiani, R. B.; Marks, P. A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene., 2007, 26(37), 5541-5552.
8. Mottet, D.; Castronovo, V. Histone deacetylases: target enzymes for cancer therapy. Clin. Exp. Metastasis., 2008, 25(2), 183-189.
9. Yang, P. M.; Lin, J. H.; Huang, W. Y.; Lin, Y. C.; Yeh, S. H.; Chen, C. C. Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate. Biochem Biophys Res Commun., 2010, 391(3), 1396-1399.
10. Marks, P. A. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim. Biophys. Acta., 2010, 1799(10-12), 717-725.
11. Noureen, N.; Rashid, H.; Kalsoom, S. Identification of typespecific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother. Pharmacol., 2010, 66(4), 625-633.
12. Jones, P.; Steinkühler, C. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr. Pharm. Des., 2008, 14(6), 545-561.
13. Zhang, L.; Fang, H.; Xu, W. Strategies in developing promising histone deacetylase inhibitors. Med. Res. Rev., 2010, 30(4), 585-602.
14. Marson, C. M. Histone deacetylase inhibitors: design, structureactivity relationships and therapeutic implications for cancer. Anticancer Agents Med. Chem., 2009, 9(6), 661-692.
15. Pontiki, E.; Hadjipavlou-Litina, D. Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives. Med. Res. Rev., 2012, 32(1), 1-165.
16. Petrella, A.; Fontanella, B.; Carratù, A.; Bizzarro, V.; Rodriquez, M.; Parente, L. Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini. Rev. Med. Chem., 2011, 11(6), 519-527.
17. Venugopal, B.; Evans, T. R. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med, Chem., 2011, 18(11), 1658-1671.
18. Tinari, N.; De Tursi, M.; Grassadonia, A.; Zilli, M.; Stuppia, L.; Iacobelli, S.; Natoli, C. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets., 2012, 12(4), 439-452.
19. Tambunan, U. S.; Bramantya, N.; Parikesit, A. A. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class IIhistone deacetylase (HDAC). BMC Bioinformatics., 2011, 12(13), s13-S23.
20. VanderMolen, K. M.; McCulloch, W.; Pearce, C. J.; Oberlies, N. H. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo)., 2011, 64(8), 525-531.
21. Atadja, P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett., 2009, 280(2), 233-241.
22. Molife, L. R.; de Bono, J. S. Belinostat: clinical applications in solid tumors and lymphoma. Exp. Opin. Investig. Drugs., 2011, 20(12), 1723-1732.
23. Younes, A.; Oki, Y.; Bociek, R. G.; Kuruvilla, J.; Fanale, M.; Neelapu, S.; Copeland, A.; Buglio, D.; Galal, A.; Besterman, J.; Li, Z.; Drouin, M.; Patterson, T.; Ward, M. R.; Paulus, J. K.; Ji, Y.; Medeiros, L. J.; Martell, R. E. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol., 2011, 12(13), 1222-1228.
24. Yang, C.; Choy, E.; Hornicek, F. J.; Wood, K. B.; Schwab, J. H.; Liu, X.; Mankin, H.; Duan, Z. Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res., 2011, 31(4), 1115-1123.
25. Lewis, E. C.; Blaabjerg, L.; Størling, J.; Ronn, S. G.; Mascagni, P.; Dinarello, C. A.; Mandrup-Poulsen, T. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet cells in vivo and in vitro. Mol. Med., 2011, 17(5-6), 369-377.
26. Venugopal, B.; Baird, R.; Kristeleit, R. S.; Plummer, R.; Cowan, R.; Stewart, A.; Fourneau, N.; Hellemans, P.; Elsayed, Y.; McClue, S.; Smit, J. W.; Forslund, A.; Phelps, C.; Camm, J.; Evans, T. R.; de Bono, J. S.; Banerji, U. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin. Cancer Res., 2013, 19(15), 4262-4672.
27. Mandl-Weber, S.; Meinel, F. G.; Jankowsky, R.; Oduncu, F.; Schmidmaier, R.; Baumann, P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br. J. Haematol., 2010, 149(4), 518-528.
28. Kozikowski, A. P.; Chen, Y.; Gaysin, A. M.; Savoy, D. N.; Billadeau, D. D.; Kim, K. H. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors nanomolar potency inhibitors of pancreatic cancer cell growth. Chem. Med. Chem., 2008, 3(3), 487-501.
29. Kozikowski, A. P.; Tapadar, S.; Luchini, D. N.; Kim, K. H.; Billadeau, D. D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem., 2008, 51(15), 4370-4373.
30. Chen, P. C.; Patil, V.; Guerrant, W.; Green, P.; Oyelere, A. K. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg. Med. Chem., 2008, 16(9), 4839-4853.
31. Jiao, J.; Fang, H.; Wang, X.; Guan, P.; Yuan, Y.; Xu, W. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido) benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. Eur. J. Med. Chem., 2009, 44(11), 4470-4476.
32. Wang, H.; Yu, N.; Song, H.; Chen, D.; Zou, Y.; Deng, W.; Lye, P. L.; Chang, J.; Ng, M.; Sun, E. T.; Sangthongpitag, K.; Wang, X.; Wu, X.; Khng, H. H.; Fang, L.; Goh, S. K.; Ong, W. C.; Bonday, Z.; Stünkel, W.; Poulsen, A.; Entzeroth, M. N-Hydroxy-1, 2-disubstituted-1Hbenzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity. Bioorg. Med. Chem. Lett., 2009, 19(5), 1403-1408.
33. Dallavalle, S.; Cincinelli, R.; Nannei, R.; Merlini, L.; Morini, G.; Penco, S.; Pisano, C.; Vesci, L.; Barbarino, M.; Zuco, V.; De Cesare, M.; Zunino, F. Design, synthesis, and evaluation of biphenyl-4-ylacrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur. J. Med. Chem., 2009, 44(5), 1900-1912.
34. Giannini, G.; Marzi, M.; Pezzi, R.; Brunetti, T.; Battistuzzi, G.; Marzo, M. D.; Cabri, W.; Vesci, L.; Pisano, C. N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(8), 2346-2349.
35. Smil, D. V.; Manku, S.; Chantigny, Y. A.; Leit, S.; Wahhab, A.; Yan, T. P.; Fournel, M.; Maroun, C.; Li, Z.; Lemieux, A. M.; Nicolescu, A.; Rahil, J.; Lefebvre, S.; Panetta, A.; Besterman, J. M.; Déziel, R. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(3), 688-692.
36. Su, H.; Yu, L.; Nebbioso, A.; Carafa, V.; Chen, Y.; Altucci, L.; You, Q. Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. Bioorg. Med. Chem. Lett., 2009, 19(22), 6284-6288.
37. Tapadar, S.; He, R.; Luchini, D. N.; Billadeau, D. D.; Kozikowski, AP. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg. Med. Chem. Lett., 2009, 19(11), 3023-3026.
38. Choi, S. E.; Weerasinghe, S. V.; Pflum, M. K. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorg. Med. Chem. Lett., 2011, 21(20), 6139-6142.
39. Oanh, D. T.; Hai, H. V.; Park, S. H.; Kim, H. J.; Han, B. W.; Kim, H. S.; Hong, J. T.; Han, S. B.; Hue, V. T.; Nam, N. H. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Bioorg. Med. Chem. Lett., 2011, 21(24), 7509-7512.
40. Rajak, H.; Agarawal, A.; Parmar, P.; Thakur, B. S.; Veerasamy, R.; Sharma, P. C.; Kharya, M. D. 2, 5-Disubstituted-1, 3, 4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(19), 5735-5738.
41. Pabba, C.; Gregg, B. T.; Kitchen, D. B.; Chen, Z. J.; Judkins, A. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(1), 324-328.
42. Choi, E.; Lee, C.; Park, J. E.; Seo, J. J.; Cho, M.; Kang, J. S.; Kim, H. M.; Park, S. K.; Lee, K.; Han, G. Structure and property based design, synthesis and biological evaluation of lactam based HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(4), 1218-1221.
43. Varasi, M.; Thaler, F.; Abate, A.; Bigogno, C.; Boggio, R.; Carenzi, G.; Cataudella, T.; Dal Zuffo, R.; Fulco, M. C.; Rozio, M. G.; Mai, A.; Dondio, G.; Minucci, S.; Mercurio, C. Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acidbased derivatives as structurally novel histone deacetylase (HDAC) inhibitors. J. Med. Chem., 2011, 54(8), 3051-364.
44. Rossi, C.; Porcelloni, M.; D'Andrea, P.; Fincham, C. I.; Ettorre, A.; Mauro, S.; Squarcia, A.; Bigioni, M.; Parlani, M.; Nardelli, F.; Binaschi, M.; Maggi, C. A.; Fattori, D. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(8), 2305-2308.
45. Zhang, Y.; Feng, J.; Jia, Y.; Wang, X.; Zhang, L.; Liu, C.; Fang, H.; Xu, W. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. J. Med. Chem., 2011, 54(8), 2823-2838.
46. Shultz, M.; Fan, J.; Chen, C.; Cho, Y. S.; Davis, N.; Bickford, S.; Buteau, K.; Cao, X.; Holmqvist, M.; Hsu, M.; Jiang, L.; Liu, G.; Lu, Q.; Patel, C.; Suresh, J. R.; Selvaraj, M.; Urban, L.; Wang, P.; Yan-Neale, Y.; Whitehead, L.; Zhang, H.; Zhou, L.; Atadja, P. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(16), 4909-4912.
47. Shultz, M. D.; Cao, X.; Chen, C. H.; Cho, Y. S.; Davis, N. R.; Eckman, J.; Fan, J.; Fekete, A.; Firestone, B.; Flynn, J.; Green, J.; Growney, J. D.; Holmqvist, M.; Hsu, M.; Jansson, D.; Jiang, L.; Kwon, P.; Liu, G.; Lombardo, F.; Lu, Q.; Majumdar, D.; Meta, C.; Perez, L.; Pu, M.; Ramsey, T.; Remiszewski, S.; Skolnik, S.; Traebert, M.; Urban, L.; Uttamsingh, V.; Wang, P.; Whitebread, S.; Whitehead, L.; Yan-Neale, Y.; Yao, Y. M.; Zhou, L.; Atadja, P. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J. Med. Chem., 2011, 54(13), 4752-4772.
48. Henkes, L. M.; Haus, P.; Jäger, F.; Ludwig, J.; Meyer-Almes, F. J. Synthesis and biochemical analysis of 2, 2, 3, 3, 4, 4, 5, 5, 6, 6, 7, 7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases. Bioorg. Med. Chem., 2012, 20(2), 985-995.
49. Guan, P.; Sun, F.; Hou, X.; Wang, F.; Yi, F.; Xu, W.; Fang, H. Design, synthesis and preliminary bioactivity studies of 1, 3, 4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors. Bioorg. Med. Chem., 2012, 20(12), 3865-3872.
50. Lee, C.; Choi, E.; Cho, M.; Lee, B.; Oh, S. J.; Park, S. K.; Lee, K.; Kim, H. M.; Han, G. Structure and property based design, synthesis and biological evaluation of lactam basedHDAC inhibitors: part II. Bioorg. Med. Chem. Lett., 2012, 22(12), 4189-4192.
51. Lai, M. J.; Huang, H. L.; Pan, S. L.; Liu, Y. M.; Peng, C. Y.; Lee, H. Y.; Yeh, T. K.; Huang, P. H.; Teng, C. M.; Chen, C. S.; Chuang, H. Y.; Liou, J. P. Synthesis and biological evaluation of 1-arylsulfonyl-5-(Nhydroxyacrylamide) indoles as potent histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem., 2012, 55(8), 3777-3791.
52. Suzuki, T.; Miyata, N. Rational design of non-hydroxamate histone deacetylase inhibitors. Mini. Rev. Med. Chem., 2006, 6(5), 515-526.
53. Jones, P.; Bottomley, M. J.; Carfí, A.; Cecchetti, O.; Ferrigno, F.; Lo Surdo, P.; Ontoria, J. M.; Rowley, M. Scarpelli, R.; Schultz-Fademrecht, C.; Steinkühler, C. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(11), 3456-3461.
54. Jones, P.; Altamura, S.; De Francesco, R.; Paz, O. G.; Kinzel, O.; Mesiti, G.; Monteagudo, E.; Pescatore, G.; Rowley, M.; Verdirame, M.; Steinkühler, C. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem., 2008, 51(8), 2350-3235.
55. Pescatore, G.; Kinzel, O.; Attenni, B.; Cecchetti, O.; Fiore, F.; Fonsi, M.; Rowley, M.; Schultz-Fademrecht, C.; Serafini, S.; Steinkühler, C.; Jones, P. Optimization of a series of potent and selective ketone histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(20), 5528-5532.
56. Scarpelli, R.; Di Marco, A.; Ferrigno, F.; Laufer, R.; Marcucci, I.; Muraglia, E.; Ontoria, J. M.; Rowley, M.; Serafini, S.; Steinkühler, C.; Jones, P. Studies of the metabolic stability in cells of 5-(trifluoroacetyl) thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(23), 6078-6082.
57. Muraglia, E.; Altamura, S.; Branca, D.; Cecchetti, O.; Ferrigno, F.; Orsale, M. V.; Palumbi, M. C.; Rowley, M.; Scarpelli, R.; Steinkühler, C.; Jones, P. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(23), 6083-6087.
58. Kinzel, O.; Llauger-Bufi, L.; Pescatore, G.; Rowley, M.; Schultz-Fademrecht, C.; Monteagudo, E.; Fonsi, M.; Gonzalez Paz, O.; Fiore, F.; Steinkühler, C.; Jones, P. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. J. Med. Chem., 2009, 52(11), 3453-3456.
59. Mwakwari, S. C.; Patil, V.; Guerrant, W.; Oyelere, A. K. Macrocyclic histone deacetylase inhibitors. Curr. Top. Med. Chem., 2010, 10(14), 1423-1440.
60. Singh, E. K.; Ravula, S.; Pan, C. M.; Pan, P. S.; Vasko, R. C.; Lapera, S. A.; Weerasinghe, S. V.; Pflum, M. K.; McAlpine, SR. Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold. Bioorg Med Chem Lett., 2008, 18(8), 2549-2554.
61. Oyelere, A. K.; Chen, P. C.; Guerrant, W.; Mwakwari, S. C.; Hood, R.; Zhang, Y.; Fan, Y. Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem., 2009, 52(2), 456-468.
62. Mwakwari, S. C.; Guerrant, W.; Patil, V.; Khan, S. I.; Tekwani, B. L.; Gurard-Levin, Z. A.; Mrksich, M.; Oyelere, A. K. Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. J. Med. Chem., 2010, 53(16), 6100-6111.
63. Montero, A.; Beierle, J. M.; Olsen, C. A.; Ghadiri, M. R. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures. J. Am. Chem. Soc., 2009, 131(8), 3033-3041.
64. Olsen, C. A.; Ghadiri, M. R. Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides. J. Med. Chem., 2009, 52(23), 7836-7846.
65. Marcaurelle, L. A.; Comer, E.; Dandapani, S.; Duvall, J. R.; Gerard, B.; Kesavan, S.; Lee, M. D.; Liu, H.; Lowe, J. T.; Marie, J. C.; Mulrooney, C. A.; Pandya, B. A.; Rowley, A.; Ryba, T. D.; Suh, B. C.; Wei, J.; Young, D. W.; Akella, L. B.; Ross, N. T.; Zhang, Y. L.; Fass, D. M.; Reis, S. A.; Zhao, W. N.; Haggarty, S. J.; Palmer, M.; Foley, M. A. An aldol-based build/couple/pair strategy for the synthesis of medium-and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J. Am. Chem Soc., 2010, 132(47), 16962-16976.
66. Auzzas, L.; Larsson, A.; Matera, R.; Baraldi, A.; Deschenes-Simard, B.; Giannini, G.; Cabri, W.; Battistuzzi, G.; Gallo, G.; Ciacci, A.; Vesci, L.; Pisano, C.; Hanessian, S. Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity. J. Med. Chem., 2010, 53(23), 8387-8399.
67. Pirali, T.; Faccio, V.; Mossetti, R.; Grolla, A. A.; Di Micco, S.; Bifulco, G.; Genazzani, A. A.; Tron, G. C. Synthesis, molecular docking and biological evaluation as HDAC nhibitors of cyclopeptide mimetics by a tandem three-component reaction and intramolecular [3+2] cycloaddition. Mol. Divers., 2010, 14(1), 109-121.
68. Singh, E. K.; Nazarova, L. A.; Lapera, S. A.; Alexander, L. D.; McAlpine, S. R. Histone Deacetylase Inhibitors: Synthesis of Cyclic Tetrapeptides and their Triazole Analogues. Tetrahedron Lett., 2010, 51(33), 4357-4360.
69. Huang, D.; Li, X.; Sun, L.; Xiu, Z.; Nishino, N. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents. J. Pept. Sci., 2012, 18(4), 242-251.
70. Paquin, I.; Raeppel, S.; Leit, S.; Gaudette, F.; Zhou, N.; Moradei, O.; Saavedra, O.; Bernstein, N.; Raeppel, F.; Bouchain, G.; Fréchette, S.; Woo, S. H.; Vaisburg, A.; Fournel, M.; Kalita, A.; Robert, M. F.; Lu, A.; Trachy-Bourget, M. C.; Yan, P. T.; Liu, J.; Rahil, J.; MacLeod, A. R.; Besterman, J. M.; Li, Z.; Delorme, D. Design and synthesis of 4-[(s-triazin-2-ylamino) methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(3), 1067-1071.
71. Fréchette, S.; Leit, S.; Woo, S. H.; Lapointe, G.; Jeannotte, G.; Moradei, O.; Paquin, I.; Bouchain, G.; Raeppel, S.; Gaudette, F.; Zhou, N.; Vaisburg, A.; Fournel, M.; Yan, P. T.; Trachy-Bourget, M. C.; Kalita, A.; Robert, M. F.; Lu, A.; Rahil, J.; Robert Macleod, A.; Besterman, J. M.; Li, Z.; Delorme, D. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(4), 1502-156.
72. Andrews, D. M.; Gibson, K. M.; Graham, M. A.; Matusiak, Z. S.; Roberts, C. A.; Stokes, E. S.; Brady, M. C.; Chresta, C. M. Design and campaign synthesis of pyridine-based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(8), 2525-2529.
73. Andrews, D. M.; Stokes, E. S.; Carr, G. R.; Matusiak, Z. S.; Roberts, C. A.; Waring, M. J.; Brady, M. C.; Chresta, C. M.; East, S. J. Design and campaign synthesis of piperidine-and thiazole-based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(8), 2580-2584.
74. Charrier, C.; Clarhaut, J.; Gesson, J. P.; Estiu, G.; Wiest, O.; Roche, J.; Bertrand, P. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. J. Med. Chem., 2009, 52(9), 3112-3115.
75. Rajak, H.; Kumar, P.; Parmar, P.; Thakur, B. S.; Veerasamy, R.; Sharma, P. C.; Sharma, A. K.; Gupta, A. K.; Dangi, J. S. Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors. Eur. J. Med. Chem., 2012, 53, 390-397.
76. Hirata, Y.; Hirata, M.; Kawaratani, Y.; Shibano, M.; Taniguchi, M.; Yasuda, M.; Ohmomo, Y.; Nagaoka, Y.; Baba, K.; Uesato, S. Antitumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain. Bioorg. Med. Chem. Lett., 2012, 22(5), 1926-1930.
77. Vaidya, A. S.; Karumudi, B.; Mendonca, E.; Madriaga, A.; Abdelkarim, H.; van Breemen, R. B.; Petukhov, P. A. Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novelseries of photoreactive benzamide probes for histone deacetylase 2. Bioorg. Med. Chem. Lett., 2012, 22(15), 5025-5030.
78. Wahhab, A.; Smil, D.; Ajamian, A.; Allan, M.; Chantigny, Y.; Therrien, E.; Nguyen, N.; Manku, S.; Leit, S.; Rahil, J.; Petschner, A. J.; Lu, A. H.; Nicolescu, A.; Lefebvre, S.; Montcalm, S.; Fournel, M.; Yan, T. P.; Li, Z.; Besterman, J. M.; Déziel, R. Sulfamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(2), 336-340.
79. Manku, S.; Allan, M.; Nguyen, N.; Ajamian, A.; Rodrigue, J.; Therrien, E.; Wang, J.; Guo, T.; Rahil, J.; Petschner, A. J.; Nicolescu, A.; Lefebvre, S.; Li, Z.; Fournel, M.; Besterman, J. M.; Déziel, R.; Wahhab, A. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(7), 1866-1870.
80. Rossi, C.; Fincham, C. I.; D'Andrea, P.; Porcelloni, M.; Ettorre, A.; Mauro, S.; Bigioni, M.; Binaschi, M.; Maggi, C. A.; Nardelli, F.; Parlani, M.; Fattori, D. 4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(22), 6767-6769.
81. Lai, M. J.; Huang, H. L.; Pan, S. L.; Liu, Y. M.; Peng, C. Y.; Lee, H. Y.; Yeh, T. K.; Huang, P. H.; Teng, C. M.; Chen, C. S.; Chuang, H. Y.; Liou, J. P. Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem., 2012, 55(8), 3777-3791.
82. Bowers, A. A.; West, N.; Newkirk, T. L.; Troutman-Youngman, A. E.; Schreiber, S. L.; Wiest, O.; Bradner, J. E.; Williams, R. M. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold. Org. Lett., 2009, 11(6), 1301-1304.
83. Huang, W. J.; Chen, C. C.; Chao, S. W.; Yu, C. C.; Yang, C. Y.; Guh, J. H.; Lin, Y. C.; Kuo, C. I.; Yang, P.; Chang, C. I. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. Eur. J. Med. Chem., 2011, 46(9), 4042-4049.
84. Klausmeyer, P.; Shipley, S. M.; Zuck, K. M.; McCloud, T. G. Histone deacetylase inhibitors from Burkholderia thailandensis. J. Nat. Prod., 2011, 74(10), 2039-2044.
85. Luo, Y.; Liu, H. M.; Su, M. B.; Sheng, L.; Zhou, Y. B.; Li, J.; Lu, W. Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(16), 4844-4846.
86. Göttlicher, M.; Minucci, S.; Zhu, P.; Krämer, O. H.; Schimpf, A.; Giavara, S.; Sleeman, J. P.; Lo Coco, F.; Nervi, C.; Pelicci, P. G.; Heinzel, T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 2001, 20(24), 6969-6978.
87. Newkirk, T. L.; Bowers, A. A.; Williams, R. M. Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors. Nat. Prod. Rep., 2009, 26(10), 1293-1320.
88. Shen, J.; Woodward, R.; Kedenburg, J. P.; Liu, X.; Chen, M.; Fang, L.; Sun, D.; Wang, P. G. Histone deacetylase inhibitors through click chemistry. J. Med. Chem., 2008, 51(23), 7417-7427.
89. Wash, P. L.; Hoffman, T. Z.; Wiley, B. M.; Bonnefous, C.; Smith, N. D.; Sertic, M. S.; Lawrence, C. M.; Symons, K. T.; Nguyen, P. M.; Lustig, K. D.; Guo, X.; Annable, T.; Noble, S. A.; Hager, J. H.; Hassig, C. A.; Malecha, J. W. Alpha-mercaptoketone based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(24), 6482-6485.
90. Dehmel, F.; Weinbrenner, S.; Julius, H.; Ciossek, T.; Maier, T.; Stengel, T.; Fettis, K.; Burkhardt, C.; Wieland, H.; Beckers, T. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles. J. Med. Chem., 2008, 51(13), 3985-4001.
91. Giannini, G.; Marzi, M.; Marzo, M. D.; Battistuzzi, G.; Pezzi, R.; Brunetti, T.; Cabri, W.; Vesci, L.; Pisano, C. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(10), 2840-2843.
92. Attenni, B.; Ontoria, J. M.; Cruz, J. C.; Rowley, M.; Schultz-Fademrecht, C.; Steinkühler, C.; Jones, P. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model. Bioorg. Med. Chem. Lett., 2009, 19(11), 3081-3084.
93. Tessier, P.; Smil, D. V.; Wahhab, A.; Leit, S.; Rahil, J.; Li, Z.; Déziel, R.; Besterman, J. M. Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(19), 5684-5688.
94. Suzuki, N.; Suzuki, T.; Ota, Y.; Nakano, T.; Kurihara, M.; Okuda, H.; Yamori, T.; Tsumoto, H.; Nakagawa, H.; Miyata, N. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. J. Med. Chem., 2009, 52(9), 2909-2922.
95. Desai, D.; Salli, U.; Vrana, K. E.; Amin, S. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(6), 2044-2047.
96. Osada, S.; Sano, S.; Ueyama, M.; Chuman, Y.; Kodama, H.; Sakaguchi, K. Fluoroalkene modification of mercaptoacetamidebased histone deacetylase inhibitors. Bioorg. Med. Chem., 2010, 18(2), 605-611.
97. Tazzari, V.; Cappelletti, G.; Casagrande, M.; Perrino, E.; Renzi, L.; Del Soldato, P.; Sparatore, A. New aryldithiolethione derivatives as potent histone deacetylase inhibitors. Bioorg. Med. Chem., 2010, 18(12), 4187-4194.
98. Conti, P.; Tamborini, L.; Pinto, A.; Sola, L.; Ettari, R.; Mercurio, C.; De Micheli, C. Design and synthesis of novel isoxazole-based HDAC inhibitors. Eur. J. Med. Chem., 2010, 45(9), 4331-4338.
99. Hou, J.; Feng, C.; Li, Z.; Fang, Q.; Wang, H.; Gu, G.; Shi, Y.; Liu, P.; Xu, F.; Yin, Z.; Shen, J.; Wang, P. Structure-based optimization of click-based histone deacetylase inhibitors. Eur. J. Med. Chem., 2011, 46(8), 3190-3200.
100. Wong, J. C.; Guo, L.; Peng, Z.; Zhang, W.; Zhang, N.; Lai, W.; Zhang, Z.; Zhang, C.; Zhang, X.; Song, S.; Pan, D.; Xie, C.; Li, J.; Ning, Z.; Lu, X.; He, Y.; Chen, L. Application of p21 and klf2 reporter gene assays to identify elective histone deacetylase inhibitors for cancer therapy. Bioorg. Med. Chem. Lett., 2011, 21(1), 110-116.
101. Botta, C. B.; Cabri, W.; Cini, E.; De Cesare, L.; Fattorusso, C.; Giannini, G.; Persico, M.; Petrella, A.; Rondinelli, F.; Rodriquez, M.; Russo, A.; Taddei, M. Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation. J. Med. Chem., 2011, 54(7), 2165-2182.
102. Huang, D.; Li, X.; Wei, Y.; Xiu, Z. A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives ashistone deacetylase inhibitors: design, synthesis and molecular modeling study. Eur. J. Med. Chem., 2012, 52, 111-122.
103. Bigioni, M.; Ettorre, A.; Felicetti, P.; Mauro, S.; Rossi, C.; Maggi, C. A.; Marastoni, E.; Binaschi, M.; Parlani, M.; Fattori, D. Set-up of a new series of HDAC inhibitors: the 5, 11-dihydrodibenzo[b, e]azepin-6-ones as privileged structures. Bioorg. Med. Chem. Lett., 2012, 22(17), 5360-5362.
104. Seo, S. Y. Multi-targeted hybrids based on HDAC inhibitors for anticancer drug discovery. Arch. Pharm. Res., 2012, 35(2), 197-200.
105. Cai, X.; Zhai, H. X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C. J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53(5), 2000-2009.
106. Rodriguez-Menendez, V.; Tremolizzo, L.; Cavaletti, G. Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone? Curr. Cancer Drug Targets, 2008, 8(4), 266-274.
107. Andrews, K. T.; Tran, T. N.; Wheatley, N. C.; Fairlie, D. P. Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr. Top. Med. Chem., 2009, 9(3), 292-308.
108. Shuttleworth, S. J.; Bailey, S. G.; Townsend, P. A. Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr. Drug Targets, 2010, 11(11), 1430-1438.